As described previously, SMAD9 is a NB-specific SEs-targeted gene mediated by MYCN and other TFs in CRC and dual luciferase assays showed that SMAD9 or MYCN knockdown reduced the activity of MYCN promoter or SMAD9 enhancer. The gene discussed is MYCN; the disease is neuroblastoma.